IBDEI13W ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19520,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,19520,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,19520,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,19521,0)
 ;;=201.90^^105^1232^83
 ;;^UTILITY(U,$J,358.3,19521,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19521,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,19521,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,19521,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,19522,0)
 ;;=785.6^^105^1232^89
 ;;^UTILITY(U,$J,358.3,19522,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19522,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,19522,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,19522,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,19523,0)
 ;;=200.20^^105^1232^90
 ;;^UTILITY(U,$J,358.3,19523,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19523,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,19523,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,19523,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,19524,0)
 ;;=202.00^^105^1232^92
 ;;^UTILITY(U,$J,358.3,19524,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19524,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,19524,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,19524,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,19525,0)
 ;;=200.10^^105^1232^91
 ;;^UTILITY(U,$J,358.3,19525,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19525,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,19525,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,19525,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,19526,0)
 ;;=273.3^^105^1232^93
 ;;^UTILITY(U,$J,358.3,19526,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19526,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,19526,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,19526,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,19527,0)
 ;;=203.00^^105^1232^103
 ;;^UTILITY(U,$J,358.3,19527,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19527,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,19527,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,19527,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,19528,0)
 ;;=203.01^^105^1232^105
 ;;^UTILITY(U,$J,358.3,19528,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19528,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,19528,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,19528,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,19529,0)
 ;;=238.6^^105^1232^108
 ;;^UTILITY(U,$J,358.3,19529,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19529,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,19529,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,19529,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,19530,0)
 ;;=205.00^^105^1232^4
 ;;^UTILITY(U,$J,358.3,19530,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19530,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,19530,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,19530,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,19531,0)
 ;;=205.01^^105^1232^6
 ;;^UTILITY(U,$J,358.3,19531,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19531,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,19531,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,19531,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,19532,0)
 ;;=205.10^^105^1232^19
 ;;^UTILITY(U,$J,358.3,19532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19532,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,19532,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,19532,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,19533,0)
 ;;=205.11^^105^1232^21
 ;;^UTILITY(U,$J,358.3,19533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19533,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,19533,1,5,0)
 ;;=5^CML,In Remission
 ;;
 ;;$END ROU IBDEI13W
